Cognitive effects of a prolonged-release formulation of galantamine (PRC) in patients with Alzheimer's disease – An open-label phase-IIIb-study

Background: Randomized controlled clinical trials have demonstrated the efficacy of galantamine-PRC in the treatment of Alzheimer's disease (AD)-patients. Objectives of this clinical trial were to further study the overall effect of galantamine-PRC on cognition and function in patients with AD. Methods: Open-label, multi-center clinical trial (GAL-DEM-3002). Patients with mild to moderate AD (NINCDS-ADRDA criteria) received 16–24mg/day galantamine-PRC for 6 months. Primary objectives were to examine the effects on cognitive function using ADAS-cog and DemTect. Response-rate at endpoint was defined as percentage…